2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaSmall Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.Peer-Reviewed Original ResearchSmall cell bladder cancerConcurrent chemoradiotherapyNeoadjuvant chemotherapySEER-Medicare databaseMedian OSLocoregional therapySEER-MedicareBladder cancerHistological subtypesOverall survivalInstitutional databaseCompare outcomesOptimal locoregional therapyAggressive histologic subtypeNon-metastatic stageNon-metastatic diseaseSEER-Medicare datasetMultivariate Cox analysisFollow-up/deathLocalized diseaseCox analysisCystectomyTreatment patternsTreatment responseMultivariate analysisPatterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older
Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.Peer-Reviewed Original ResearchMuscle invasive bladder cancerPatterns of chemotherapy useRadiation therapyReceipt of chemotherapyChemotherapy useMultivariate logistic regressionConcurrent chemotherapyOverall survivalBladder cancerFactors associated with receipt of chemotherapyMaximum transurethral resection of bladder tumorNational Cancer Institute comorbidity indexTransurethral resection of bladder tumorAlternative to radical cystectomyAssociated with superior OSReceipt of concurrent chemotherapyResection of bladder tumorCurative-intent RTLow dose gemcitabineUtilization of chemotherapyLocalized bladder cancerInvasive bladder cancerFactors associated with receiptYear of diagnosisSuperior disease controlPD34-09 PATTERNS OF CHEMOTHERAPY USE WITH PRIMARY RADIOTHERAPY FOR LOCALIZED BLADDER CANCER
Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Montgomery R, Wright J. PD34-09 PATTERNS OF CHEMOTHERAPY USE WITH PRIMARY RADIOTHERAPY FOR LOCALIZED BLADDER CANCER. Journal Of Urology 2024, 211: e722. DOI: 10.1097/01.ju.0001008768.36634.79.09.Peer-Reviewed Original ResearchMP15-18 MOLECULAR CHARACTERIZATION OF URETHRAL CANCER AND COMPARISON WITH BLADDER CANCER
Ghali F, Galipeau P, Yang M, Dill-McFarland K, Ha G, Montgomery R, Wright J, Lam H. MP15-18 MOLECULAR CHARACTERIZATION OF URETHRAL CANCER AND COMPARISON WITH BLADDER CANCER. Journal Of Urology 2024, 211: e237. DOI: 10.1097/01.ju.0001009500.87761.bf.18.Peer-Reviewed Original ResearchAdjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.Peer-Reviewed Original ResearchNational Cancer DatabaseAdjuvant chemotherapyReceipt of ACRadical cystectomyBladder cancerOverall survivalAssociated with significantly longer OSAssociated with OS benefitNon-metastatic bladder cancerMultivariate Cox regression analysisPrevalence of adenocarcinomaSquamous cell histologyMultivariate Cox regressionCox regression analysisMultivariate logistic regressionAssociated with lower oddsAssociated with greater oddsNeuroendocrine histologyLonger OSOS benefitCell histologyHistological subtypesCancer DatabaseClinicopathological featuresCox regression
2023
Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress
Rahman S, Ryan S, Kim J, Kenney P, Ghali F. Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress. European Urology Focus 2023, 9: 861-862. PMID: 38042649, DOI: 10.1016/j.euf.2023.11.011.Peer-Reviewed Original ResearchMetastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Ghali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaVariant histologySacituzumab govitecanTrop-2Nectin-4Antibody-drug conjugatesMetastatic lesionsADC targetCytoplasmic stainingProminent cytoplasmic stainingMembrane stainingTrop-2 expressionCytoplasmic protein expressionMetastatic sitesAutopsy studyUrothelial carcinomaMetastatic tumorsSquamous differentiationClinical relevanceCancer expressionHistologyNeuroendocrineProtein expressionMRNA levelsProtein levelsThe Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
Ghali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.Peer-Reviewed Original Research
2022
Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
Ghali F, Zhao Y, Patel D, Jewell T, Yu E, Grivas P, Montgomery R, Gore J, Etzioni R, Wright J. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. European Urology Open Science 2022, 47: 58-64. PMID: 36601043, PMCID: PMC9806712, DOI: 10.1016/j.euros.2022.11.003.Peer-Reviewed Original ResearchExternal validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study
Raheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.Peer-Reviewed Original ResearchConceptsNew-onset CKDCKD stageChronic kidney disease developmentExternal validationCKD stage ICT1 renal massesKidney disease developmentPreoperative eGFRPatient ageConsecutive patientsMulticenter studyTumor sizePartial nephrectomyRenal massesProgression rateGood calibration propertiesStage IProgression probabilityPatientsNomogramIndividual riskCKDDisease developmentEGFRMedian valueMP56-20 SURROGATE ENDPOINTS AS PREDICTORS OF SURVIVAL IN METASTATIC UROTHELIAL CANCER TRIALS
Ghali F, Patel D, Jewell T, Gore J, Wright J. MP56-20 SURROGATE ENDPOINTS AS PREDICTORS OF SURVIVAL IN METASTATIC UROTHELIAL CANCER TRIALS. Journal Of Urology 2022, 207: e980. DOI: 10.1097/ju.0000000000002639.20.Peer-Reviewed Original ResearchClinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer
Miron B, Hawley J, Geynisman D, Mouw K, Sfakianos J, Weg E, Ghali F, Wright J, Grivas P, Khaki A. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances In Oncology 2022, 2: 213-225. DOI: 10.1016/j.yao.2022.02.007.Peer-Reviewed Original ResearchPD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?
Ghali F, Roudier M, Vakar-Lopez F, Garcia J, Wang Y, Ha G, Grivas P, Lee J, Yu E, Montgomery B, Hsieh A, Wright J, Lam H. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS? Journal Of Urology 2022, 207: e913. DOI: 10.1097/ju.0000000000002630.09.Peer-Reviewed Original ResearchPD15-07 RENAL CELL CARCINOMA PARANEOPLASTIC SYNDROME SCORE: CONSTRUCTION AND VALIDATION
Soliman S, Noyes S, Meagher M, Rosenberg J, Leonard A, Hakimi K, Yuan J, Walia A, Saidian A, Ghali F, Javier-Desloges J, Patel D, McKay R, Derweesh I, Lane B. PD15-07 RENAL CELL CARCINOMA PARANEOPLASTIC SYNDROME SCORE: CONSTRUCTION AND VALIDATION. Journal Of Urology 2022, 207: e264. DOI: 10.1097/ju.0000000000002547.07.Peer-Reviewed Original ResearchImpact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyTechniques of robotic assisted partial nephrectomy with renal vein tumor thrombectomy and reconstruction: UCSD experience
Patel D, Ghali F, Greear G, Holst D, Derweesh I. Techniques of robotic assisted partial nephrectomy with renal vein tumor thrombectomy and reconstruction: UCSD experience. Urology Video Journal 2022, 13: 100124. DOI: 10.1016/j.urolvj.2022.100124.Peer-Reviewed Original ResearchPartial nephrectomyTumor thrombusRenal veinSegmental branchesImmediate post-operative complicationsPost-operative day twoT3 renal cell carcinomaPost-operative day threePost-operative complicationsTotal operative timeWarm ischemia timeMulti-institutional analysisMain renal veinRenal cell carcinomaRobotic partial nephrectomyInvasive partial nephrectomyBowel mobilizationPT3a diseaseSided tumorsFinal pathologyBlood lossRenal functionTumor thrombectomyThird patientOperative timeDoes presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis.
Saidian A, Walia A, Patil D, Saito K, Patel D, Nguyen M, Chakoumakos M, Ghali F, Narasimhan R, Perry J, Meagher M, Yasuda Y, Fujii Y, Master V. Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis. Journal Of Clinical Oncology 2022, 40: 325-325. DOI: 10.1200/jco.2022.40.6_suppl.325.Peer-Reviewed Original ResearchRenal cell carcinomaProgression-free survivalKaplan-Meier analysisCancer-specific survivalIndependent risk factorMultivariable analysisDiabetes mellitusRisk factorsOverall survivalCell carcinomaStage ICox regression multivariable analysisImpact of DMPatients' oncological outcomesNon-diabetic patientsRegression multivariable analysisOncologic effectCause mortalityOncological outcomesDiabetic patientsMulticenter analysisMeier analysisMale sexRCC patientsStage subgroupsDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive marginsDisparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic
Javier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.Peer-Reviewed Original ResearchConceptsTelemedicine utilizationMultivariable logistic regression analysisLogistic regression multivariable analysisRegression multivariable analysisSingle academic institutionLogistic regression analysisUse of telemedicineCOVID-19 pandemicNon-Hispanic whitesUrology patientsPatient characteristicsPrimary outcomeMedicaid insuranceMultivariable analysisRetrospective studyTelemedicine appointmentsUrologic conditionsProvider ageProvider trainingClinic locationProvider sexPatientsBackward model selectionZip codesVisits